Cancer care in Sweden
The quality of cancer care in Sweden is high and survival rates for many types of cancer are above the European average. Although the economic and social impact of cancer on society is lower than the European average, Sweden spends more than an average European country on cancer relative to its incidence. Cancer therefore continues to represent a substantial economic and social cost.
All.Can Sweden initiative
Sweden’s All.Can initiative was officially launched in September 2017 with the establishment of the Cancer Commission, a project sponsored by Bristol-Myers Squibb, Amgen and Microsoft Sweden. The aim of the Commission is to improve cancer care and to create sustainable and equal circumstances for the care of all cancer patients in Sweden. The Cancer Commission is tasked with developing proposals for improvements in Swedish cancer care, in dialogue with patient organisations, healthcare representatives, researchers, politicians and representatives from the health technology sector. The Commission aims to improve cancer prevention, diagnosis and treatment, as well as rehabilitation.
The Cancer Commission published its policy report in June 2018. The full report is available in Swedish, and a summary version is available in English.
The Commission is chaired by Mr. Lars Leijonborg, former Leader of the Liberal Party, former Education and Research Minister and former Chairman of the Karolinska Institute. The other members of the Commission possess a range of competencies and experiences in cancer care and including patient representatives, oncologists and politicians.
Website: http://cancerkommissionen.se
Activities and milestones
- Round-table seminars across five regions to initiate local discussion and get regional insights
- Thematic meetings with invited experts to increase knowledge and understanding
- Active contribution to the cancer policy work of the Ministry of Health and Social Affairs
- Discussions with parliamentary parties in preparation for the 2018 general election
- Launch of policy recommendations in 2018.
Steering group
Lars Leijonborg
Chairman of the Cancer Commission, former Leader of the Liberal Party, former Education and Research Minister, and former Chariman of the Karolinska Institute
Ulla Wilking
Nurse and Researcher at the Karolinska Institute
Penilla Gunther
Member of Parliament for the Christian Democrats and member of the Business and Industry Parliamentary Committee
Mona Boström
Former Director of Stockholm County Council and Region Halland, and former National Coordinator to the Swedish government with responsibility for the development of National Quality Registries in healthcare
Eva Hansen
Secretary-General of CancerRehabFonden
Professor Bengt Glimelius
Professor Emeritus of Oncology at Uppsala University
Kaisa Karro
Chairman of Health and Medical Care in the Region of Östergötland; member of the Social Democratic Party
All.Can Sweden calls for national IT standards and better coordination of care
All.Can Sweden has published a policy report calling for national IT standards and improved coordination.
Swedish All.Can initiative launched
The All.Can initiative was officially launched in Sweden with the announcement of the Cancer Commission.
All.Can Sweden policy report
All.Can Sweden launched its policy report in June 2018. National Cancer Plan 2020: Improved access and reduced mortality – it is time to escalate the fight against cancer! is available in Swedish, with a summary version available in English.
- Download the full report in Swedish from the Cancer Commission’s website
- Download the summary report in English
Disclaimer:
The All.Can initiative is made up of leading representatives of patient organisations, policymakers, healthcare professionals, science and industry. All the publications produced as part of this initiative reflect a consensus of All.Can members, who retain full editorial control. The All.Can initiative in Sweden was created with the financial support of Bristol-Myers Squibb, Amgen and Microsoft Sweden. None of the content developed from All.Can discussions and activities contains direct or indirect references to specific medicinal products or therapies.
All.Can is a trademark of The Health Policy Partnership Ltd.